Merck KGaA

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of € 12.8 billion in 66 countries. Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Company Growth (employees)
Darmstadt, DE
Size (employees)
51,480 (est)+2%
Merck KGaA is headquartered in Darmstadt, DE

Merck KGaA Office Locations

Merck KGaA has an office in Darmstadt
Darmstadt, DE (HQ)
250 Frankfurter Str.

Merck KGaA Data and Metrics

Merck KGaA Financial Metrics

Merck KGaA's revenue was reported to be €12.8 b in FY, 2015 which is a 13% increase from the previous period.

Revenue (FY, 2015)

12.8 b

Revenue growth (FY, 2014 - FY, 2015), %


Gross profit (FY, 2015)

8.8 b

Gross profit margin (FY, 2015), %


Net income (FY, 2015)

1.1 b

EBIT (FY, 2015)

1.8 b

Market capitalization (19-Jul-2017)

43.6 b

Closing share price (19-Jul-2017)


Cash (31-Dec-2015)

832.2 m


52.4 b
Merck KGaA's current market capitalization is €43.6 b.
EURFY, 2014FY, 2015


11.4 b12.8 b

Revenue growth, %


Cost of goods sold

3.5 b4.1 b

Gross profit

7.8 b8.8 b

Gross profit Margin, %


Sales and marketing expense

3.6 b4 b

R&D expense

1.7 b1.7 b

General and administrative expense

608.6 m719.9 m

Operating expense total

5.9 b6.5 b

Depreciation and amortization

1.4 b1.5 b


1.8 b1.8 b

EBIT margin, %


Interest expense

159.8 m291.6 m

Interest income

30.6 m32 m

Pre tax profit

1.6 b1.5 b

Income tax expense

392.2 m368 m

Net Income

1.2 b1.1 b
EURY, 2014Y, 2015


2.9 b832.2 m

Total Assets

26 b38 b

Total Debt

3.6 b9.6 b

Total Liabilities

14.2 b25.2 b
EURFY, 2014FY, 2015

Cash From Operating Activities

2.7 b2.2 b
Y, 2015


28.4 x


23.9 x

Merck KGaA Market Value History

Merck KGaA Revenue Breakdown

Traffic Overview of Merck KGaA

Merck KGaA Online and Social Media Presence

Merck KGaA News and Updates

This Algorithm Is Trying to Save Your Eyesight

A team of Google researchers unveils a transformative technology.

Editorial: The EpiPen Outrage Continues

It’s time for Congress to stop letting pharmaceutical companies get away with price gouging on lifesaving drugs.

Mylan CEO sold $5m worth of stock while EpiPen price drew scrutiny

Heather Bresch sold 100,200 of shares on same day as release of earnings Transaction was ‘part of a 10b5 plan’, which curtails insider trading suspicions Heather Bresch, the CEO at the center of EpiPen’s 471% price hike, sold 100,200 of her shares earlier this month and earned more than $5m from t…

Editorial: Another Drug Pricing Ripoff

The rapid price increase in the EpiPen is an extreme example of the common practice of raising prices solely to reap higher profits.

Big Pharma’s Bets: Where They’re Investing Across Digital Health, Biotech, And Medical Devices

The pharmaceuticals industry is changing rapidly as drug profit margins are squeezed and revenue growth slows, which has led many pharma giants to look to private markets. Many pharma companies are effectively outsourcing the R&D of some newer and experimental … Continued

BRIEF-Merck KGaA says Zeiss, Hamilton Thorne to join global fertility alliance

* Says welcomes Zeiss and Hamilton Thorne as new members of global fertility alliance Source text for Eikon: Further company coverage:

Merck KGaA Company Life and Culture

You may also be interested in